Many donor livers are too unhealthy to be transplanted and go to waste, despite one in six patients dying while waiting for a new liver. The main reason for discarding a donor liver is that it contains too much fat.
By 2030, it’s estimated that over half of donor livers will be discarded.
Orman ES et al. (2015) doi: 10.1002/lt.24160
Obesity and age are rapidly becoming the main combined reason for liver failure, where a transplant has become the only solution. In fact, obesity and age are the main risk factors behind many chronic diseases that result in four out of ten deaths. This statistic continues to rise, as our population become older and more obese.
Fat in the liver contributes to more deaths than all cancers combined.
Institute for Health Metrics and Evaluation. Used with permission. All rights reserved
‘Big data’ is delivering on its promise to improve drug development, with machine learning (‘AI’) decoding disease much cheaper, and high-throughput workflows decoding network biology much faster. Ochre Bio’s approach is firmly rooted in such computational and systems-driven learning. However, our goal is also to decode substantially better.
Not just fail fast, but fail less with the correct type of big data with which to train our models. Ochre Bio brings an extra dimension to drug development data, called deep phenotyping. Deep phenotyping combines genetics, advanced tissue imaging, cellular genomics (single-cell and spatial sequencing), and machine learning, to study disease and gene systems at a tissue level.
Our 100% human focus involves the deep phenotyping of human biobanks, deep phenotyping of genetically perturbed human micro-organs (in vitro) models and the deep phenotyping of diseased human organs perfused outside of the body.
This 100% human approach to data provides a distinct advantage when studying complex age-associated and chronic diseases that require more than simple single-target therapies.
Pretreat suboptimal donor livers; treat non-symptomatic cirrhosis.
Prevent recurrence of fatty liver post-transplant; treat morbid obesity.
Buy more time for those with end-stage disease; treat decompensated cirrhosis.
Ochre Bio was founded out of 15 years leading liver genomics research and experience in bringing advanced therapies to market. We really love what we do, and are always on the lookout for new team members who aren't afraid to think out of the box.
We have compiled a highly specialised group of advisors, consultants, and investors to help craft our strategy. Our combination of US and European investors, with traditional life sciences as well as genomics and technology expertise, underscores the type of company we are building.